Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and nivolumab with or without concurrent intracranial stereotactic radiotherapy in melanoma brain metastases
2020-005647-24Phase 2Terminated
- Sponsor
- Melanoma Institute Australia
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in melanoma and brain metastases (2 arms), sponsored by Melanoma Institute Australia. Primary endpoint: Neurological-specific death at 1 year. Started Jan 2021; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2020-005647-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005647-24.